PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

REC'D 13 FEB 2006

(PCT Article 36 and Rule 70)

WIPO PCT

Applicant's or agent's file reference WPP87096	FOR FURTHER ACTIO	FURTHER ACTION See Form PCT/IPEA/416						
International application No. PCT/GB2004/000403	International filing date (daylim 05.02.2004	onth/year)	Priority date (day/month/year) 05.02.2003					
International Patent Classification (IPC) or national classification and IPC A61K9/70								
Applicant STRAKAN LIMITED et al.								
Authority under Article 35 and trai	ismitted to the applicant acc	ording to Article 36.	International Preliminary Examining					
2. This REPORT consists of a total of	of 5 sheets, including this co	over sheet.						
3. This report is also accompanied b			·					
a. sent to the applicant and t	o the International Bureau) a	total of sheets, as	s follows:					
sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).								
sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.								
b. (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)), containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).								
4. This report contains indications re	elating to the following items	:						
☑ Box No. I Basis of the op	inion							
☐ Box No. II Priority								
		novelty, inventive	step and industrial applicability					
☐ Box No. IV Lack of unity of	finvention		a de la constantación					
applicability; ci	applicability; citations and explanations supporting such statement							
☐ Box No. VI Certain docum		ion						
	s in the international application							
☐ Box No. VIII Certain observ	ations on the international ap	pplication						
Date of submission of the demand	. Da	ate of completion of th	is report					
12.08.2004		0.02.2006						
Name and mailing address of the internation preliminary examining authority:	onal AL	uthorized Officer	John Peterson Peterson P					
European Patent Office D-80298 Munich	K	ardas-Llorens, E						
Tel. +49 89 2399 - 0 Tx: 523 Fax: +49 89 2399 - 4465	3656 epmu d	elephone No. +49 89 2	2399-8652					

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/GB2004/000403

	Box N	lo. I	Basis of the report
1.	With r	egard unless	I to the language, this report is based on the international application in the language in which it was otherwise indicated under this item.
	W	/hich i] inter] oub	port is based on translations from the original language into the following language, is the language of a translation furnished for the purposes of: Immational search (under Rules 12.3 and 23.1(b)) Illication of the international application (under Rule 12.4) Imparimentational preliminary examination (under Rules 55.2 and/or 55.3)
2.	have	heen	d to the elements* of the international application, this report is based on <i>(replacement sheets whic furnished to the receiving Office in response to an invitation under Article 14 are referred to in this priginally filed" and are not annexed to this report):</i>
	Descr	ription	ı, Pages
	1-22		as originally filed
	Claim	ıs, Nur	mbers
	1-30		as originally filed
		a sequ	uence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing
3.		the the the the	mendments have resulted in the cancellation of: e description, pages e claims, Nos. e drawings, sheets/figs e sequence listing (specify): y table(s) related to sequence listing (specify):
4.	had i Supp [[]	not be olemend the last the last the last the last the last any last the last the last last last last last last last last	eport has been established as if (some of) the amendments annexed to this report and listed below een made, since they have been considered to go beyond the disclosure as filed, as indicated in the ntal Box (Rule 70.2(c)). de description, pages e claims, Nos. de drawings, sheets/figs de sequence listing (specify): my table(s) related to sequence listing (specify):
	*	If it	tem 4 applies, some or all of these sheets may be marked "superseded."

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/GB2004/000403

Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability						
1.	The obv	questions whether the claimed invention appears to be novel, to involve an inventive step (to be non- ious), or to be industrially applicable have not been examined in respect of:				
		the entire international application	ne entire international application,			
	\boxtimes	claims Nos. 30	aims Nos. 30			
		because:	cause:			
	Ø	the said international application, or the said claims Nos. 30 relate to the following subject matter which does not require an international preliminary examination (specify):				
		see separate sheet				
		the description, claims or drawings (indicate particular elements below) or said claims Nos. are so unclear that no meaningful opinion could be formed (specify):				
		the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.				
		no international search report h	as be	een established for the said claims Nos.		
		the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:				
		the written form		has not been furnished		
				does not comply with the standard		
		the computer readable form		has not been furnished		
				does not comply with the standard		
		the tables related to the nucleo not comply with the technical re	tide a equire	and/or amino acid sequence listing, if in computer readable form only, do ements provided for in Annex C-bis of the Administrative Instructions.		
		See separate sheet for further	detai	ls		

International application No. PCT/GB2004/000403

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

No: Claims

1-30

Inventive step (IS)

Yes: Claims

No:

Claims

1-30

Industrial applicability (IA)

Yes: Claims

1-29

No: Claims

2. Citations and explanations (Rule 70.7):

see separate sheet

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (SEPARATE SHEET)

International application No.

PCT/GB2004/000403

Novelty:

The subject-matter of claim 1 is directed to an adhesive patch wherein the adhesive is an acrylic adhesive containing non-acidic hydroxyl moieties. Thus, independently from each other documents D1, D2, D4, D6, D7disclose an adhesive patch as presently claimed (see the indications in the search report). Moreover, D2, D4, D6 disclose the subject-matter of claim 30. Thus, the subject-matter of claims 1 and 30 is not new.

Inventive Step:

According to present page 5, the problem to be solved is to provide transdermal patches for the delivery of antiemetics, in particular granisetron. This has been presently achieved by adhesives comprising hydroxyl groups.

In the same manner documents D1, D2, D4, D6, D7 apply adhesive patches comprising hydroxyl groups for the delivery of antiemetics. The delivery of antiemetics by using transdermal patches is also obvious for a skilled person in the light of the disclosures of D5 and D8. Thus, the subject-matter of claims 1-30 does not involve an inventive step.

Claim 30:

For the assessment of the present claim 30 on the question whether it is industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.